Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study
Bożena Katarzyna Budziszewska(Instytut Hematologii i Transfuzjologi), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Agnieszka Pluta, Monika Mordak‐Domagała(Cells Therapy (Poland)), Anna Dmoszyńska(1 Military Clinical Hospital with Outpatient Clinic), Agnieszka Wierzbowska(Medical University of Lodz), Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi), Anna Ejduk(Institute for Transfusion Medicine), Justyna Gajkowska-Kulik(Nicolaus Copernicus University), Krzysztof Mądry(Medical University of Warsaw), Sebastian Giebel(The Maria Sklodowska-Curie National Research Institute of Oncology), Joanna Mańko(Medical University of Lublin), Waldemar Sawicki(National Academy of Medicine), Andrzej Lange(Cells Therapy (Poland)), K Sułek(National Academy of Medicine), Janusz Kłoczko(University Clinical Hospital In Bialystok), Elżbieta Patkowska(Institute for Transfusion Medicine), Przemysław Biliński(Uniwersytet Kaliski im. Prezydenta Stanisława Wojciechowskiego), Sławomira Kyrcz‐Krzemień(Medical University of Silesia), Jarosław Piszcz(Medical University of Białystok), Małgorzata Raźny, Małgorzata Całbecka(Provincial Polyclinical Hospital in Toruń), Jerzy Hołowiecki(Medical University of Silesia), Tadeusz Robak(Medical University of Lodz), Aleksandra Hołowiecka-Goral(Institute for Transfusion Medicine), W Wiktor-Jędrzejczak(Medical University of Warsaw), Maria Nowakowska-Domagała(Kielce University of Technology)
Cited by 13
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k